Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Sadoff

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
The American Journal of Tropical Medicine and Hygiene|July 1, 1996
Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United StatesD M Gordon, P E Duffy, D G Heppner, et al.
The Journal of Infectious Diseases|June 1, 1993
Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteersJ L Sanchez, A F Trofa, D N Taylor, et al.
The New England Journal of Medicine|February 24, 1991
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study GroupE J Ziegler, C J Fisher, C L Sprung, et al.
Vaccine|April 1, 1995
Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2K L Kotloff, G A Losonsky, J P Nataro, et al.
Infection and Immunity|June 1, 1992
Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigenK L Kotloff, D A Herrington, T L Hale, et al.
The Journal of Pediatrics|August 7, 2001
Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacyS J Vessey, C Y Chan, B J Kuter, et al.
Infection and Immunity|May 1, 1996
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malariaD E Lanar, J A Tine, C de Taisne, et al.
Lancet (London, England)|January 18, 1997
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adultsD Cohen, S Ashkenazi, M S Green, et al.
The Journal of Infectious Diseases|August 1, 1996
Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomesD G Heppner, D M Gordon, M Gross, et al.
Vaccine|June 1, 1996
Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of KenyaJ A Sherwood, R S Copeland, K A Taylor, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
The American Journal of Tropical Medicine and Hygiene|July 1, 1996
Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United StatesD M Gordon, P E Duffy, D G Heppner, et al.
The Journal of Infectious Diseases|June 1, 1993
Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteersJ L Sanchez, A F Trofa, D N Taylor, et al.
The New England Journal of Medicine|February 24, 1991
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study GroupE J Ziegler, C J Fisher, C L Sprung, et al.
Vaccine|April 1, 1995
Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2K L Kotloff, G A Losonsky, J P Nataro, et al.
Infection and Immunity|June 1, 1992
Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigenK L Kotloff, D A Herrington, T L Hale, et al.
The Journal of Pediatrics|August 7, 2001
Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacyS J Vessey, C Y Chan, B J Kuter, et al.
Infection and Immunity|May 1, 1996
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malariaD E Lanar, J A Tine, C de Taisne, et al.
Lancet (London, England)|January 18, 1997
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adultsD Cohen, S Ashkenazi, M S Green, et al.
The Journal of Infectious Diseases|August 1, 1996
Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomesD G Heppner, D M Gordon, M Gross, et al.
Vaccine|June 1, 1996
Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of KenyaJ A Sherwood, R S Copeland, K A Taylor, et al.
Pageof 12